Myovant's Relugolix Shows Promising Profile For Endometriosis Pain

 
• By Jessica Merrill

The first Phase III trial testing relugolix combination therapy in endometriosis pain showed efficacy with minimal bone mineral density loss, an issue with AbbVie's rival drug Orilissa. An US NDA was also filed in prostate cancer.

A chess king last stand as a true winner.Money game concept. Copy space.
Myovant's Orilissa appears to have a competitive profile • Source: Shutterstock

More from Clinical Trials

More from R&D